Sugi Predict

Sugi Predict / Compounds / SCHEMBL4139797

SCHEMBL4139797

SCHEMBL4139797

O=C(O)c1ccc2cc3n(c2c1)C=CNc1ccccc1-3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ TTR P02766 1/20 0.36
▸ ACLY P53396 2/20 0.36
▸ PTPRC P08575 2/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ SRD5A2 P31213 2/20 0.34
▸ SRD5A1 P18405 1/20 0.34
▸ NR1H2 P55055 1/20 0.33
▸ NR1H3 Q13133 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ AURKA O14965 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4822220 0.89 RPS6KA3 (0.40) KMT2AKDM4EALDH1A1MEN1RAB9A
SCHEMBL4829868 0.80 KMT2A (0.37) KMT2AKDM4EALDH1A1HPGDMEN1
SCHEMBL3244153 0.76 SRD5A2 (0.43) KMT2APOLBTTRACLYPTPRC
SCHEMBL4148741 0.73 KMT2A (0.38) KMT2APOLBTTRACLYPTPRC
SCHEMBL3075059 0.73 TBXA2R (0.36) KMT2APOLBTTRACLYPTPRC
SCHEMBL4148744 0.73 KMT2A (0.38) KMT2APOLBTTRACLYPTPRC
SCHEMBL4144644 0.72 RPS6KA2 (0.47) —
SCHEMBL3236134 0.71 KMT2A (0.38) KMT2APOLBTTRACLYPTPRC
SCHEMBL4144647 0.71 KDM4E (0.32) KDM4EALDH1A1HPGD
SCHEMBL4826983 0.70 SLC40A1 (0.36) KMT2APOLBACLYFGFR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090136449-A1 Tetracyclic Indole Derivatives as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-05-28 — — US disclosed
US-7348425-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-25 — — US disclosed
US-7153848-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-26 — — US disclosed
US-20060166964-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 — — US disclosed
US-20060046983-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166964-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 KMT2A 3626/4885POLB 89/4885TTR 3190/4885
US-20090136449-A1 Tetracyclic Indole Derivatives as Antiviral Agents IDO1, IDO2, ZC3HAV1 KMT2A 3385/4885POLB 4396/4885TTR 1033/4885
US-20060046983-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 KMT2A 3626/4885POLB 89/4885TTR 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.